Skip to content Skip to footer
Zymeworks

Zymeworks’ Zanidatamab Receives the NMPA’s Conditional Approval for the Treatment of Biliary Tract Cancer

Shots: The NMPA has granted conditional approval to zanidatamab for the treatment of pts with previously treated, inoperable or metastatic HER2+ biliary tract cancer (BTC) following the CHMP’s positive opinion in Apr 2025 Approval was based on P-IIb (HERIZON-BTC-01) trial, which assessed anti-tumor activity of zanidatamab monotx. in HER2+ inoperable & advanced or metastatic BTC Approval…

Read more

Life Sciences Top 20 2022

Top 20 Life Sciences Deals of 2022 by Total Deal Value

Shots: The technological advancement, shared cost, and the pursuit of combined extensive research are amongst the few pragmatic and mutual benefits that come with collaborations. Moreover, the risks involved in drug development plans get minimalized by opening the doors to new opportunities and commercialization When it comes to life science collaborations, companies seek beyond the…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]